Loading…
Regeneron Pharmaceuticals, Inc. is projected to rise to $667.11 by 2027, a +6% move from its current price of $627.74. REGN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $616.72 | $627.94 | $639.37 | +0.03% |
| May 30 | $612.33 | $628.15 | $644.37 | +0.06% |
| May 31 | $609.03 | $628.35 | $648.28 | +0.10% |
| Jun 1 | $606.29 | $628.55 | $651.63 | +0.13% |
| Jun 2 | $603.91 | $628.75 | $654.63 | +0.16% |
| Jun 3 | $601.78 | $628.96 | $657.36 | +0.19% |
| Jun 4 | $599.85 | $629.16 | $659.91 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $599.85 | $629.16 | $659.91 | +0.23% |
| Week 2 | $589.44 | $630.58 | $674.60 | +0.45% |
| Week 3 | $581.88 | $632.01 | $686.46 | +0.68% |
| Week 4 | $575.79 | $633.44 | $696.86 | +0.91% |
| Week 5 | $570.63 | $634.87 | $706.35 | +1.14% |
| Week 6 | $566.13 | $636.31 | $715.19 | +1.37% |
| Week 7 | $562.12 | $637.75 | $723.56 | +1.59% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. It develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
It offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. The company was incorporated in 1988 and is based in Tarrytown, New York.
Regeneron Pharmaceuticals, Inc. (REGN) is a healthcare company. The current price is $638.88. Its market capitalization is $66.98B, and it is ranked 252. The forecast suggests a path from the current level toward higher values over the coming years, with 2026 at the current price and higher averages projected in later years, culminating in 2050 at an avg of $3,534.40 and a max of $5,798.76.
A major floor 14.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 22.0% above — a clean break opens room to run.
A major ceiling 29.4% above — clearing it would confirm fresh momentum.
Key REGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of REGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $638.72 | Sell | $638.82 | Sell |
| MA 10 | $658.46 | Sell | $654.76 | Sell |
| MA 20 | $683.61 | Sell | $678.53 | Sell |
| MA 50 | $724.68 | Sell | $712.18 | Sell |
| MA 100 | $747.17 | Sell | $721.46 | Sell |
| MA 200 | $694.05 | Sell | $710.31 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 29.55 | Buy |
| Stoch RSI (14) | 16.85 | Buy |
| CCI (20) | -112.29 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -5.89 | Sell |
| ROC (12) | -12.19 | Sell |
| Bollinger %B (20,2) | 0.11 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.44 | Sell |
| Awesome (5,34) | -72.41 | Sell |
| Ultimate (7,14,28) | 21.25 | Buy |
| Momentum (10) | -95.67 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 628.14 | Sell |
| ADX (14) | 24.07 | Sell |
| ATR (14) | 11.71 | Info |
The 30-day technical picture shows neutral sentiment with RSI14 at 30. The 50-day moving average is $729.49 and the 200-day moving average is $693.36, placing the near-term price below the 50-day average.
The key support level is $629.68 and the resistance level is $766.02. The 30-day price range spans from $563.63 to $724.18, and the annualized volatility is 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $627.74 | $627.74 | $828.16 | 0% | Neutral | |
| $544.98 | $667.11 | $854.77 | +6% | Neutral | |
| $603.02 | $751.63 | $988.22 | +20% | Neutral | |
| $649.57 | $821.90 | $1,103.10 | +31% | Bullish | |
| $715.12 | $916.90 | $1,252.38 | +46% | Bullish | |
| $817.13 | $1,060.36 | $1,470.90 | +69% | Bullish | |
| $832.41 | $1,092.28 | $1,536.47 | +74% | Bullish | |
| $840.50 | $1,114.42 | $1,587.71 | +78% | Bullish | |
| $884.69 | $1,184.62 | $1,707.70 | +89% | Bullish | |
| $923.57 | $1,248.31 | $1,819.39 | +99% | Bullish | |
| $1,251.31 | $1,763.71 | $2,693.03 | +181% | Bullish | |
| $2,309.98 | $3,491.34 | $5,712.78 | +456% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $627.74 | $627.74 | $733.41 | +0.00% |
| June 2026 | $536.96 | $626.39 | $744.90 | -0.22% |
| July 2026 | $551.02 | $646.50 | $776.08 | +3.21% |
| August 2026 | $561.64 | $661.93 | $800.38 | +2.39% |
| September 2026 | $555.04 | $656.58 | $798.63 | -0.81% |
| October 2026 | $554.96 | $658.73 | $805.56 | +0.33% |
| November 2026 | $565.31 | $673.02 | $826.92 | +2.17% |
| December 2026 | $562.03 | $671.03 | $828.16 | -0.30% |
Click any year to see its month-by-month REGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The REGN price prediction for 2026 points to an average of $627.74 (low $627.74, high $828.16) — a potential gain of 0% on today's $627.74. A consolidation phase looks the most probable path here.
In 2027, REGN is projected to trade between $544.98 and $854.77, averaging $667.11 — a potential gain of +6% from today's $627.74. That is up +6% on the projected 2026 average. Price action looks broadly range-bound.
Regeneron Pharmaceuticals, Inc.'s 2028 outlook centres on $751.63, within a $603.02 to $988.22 range. That is up +13% on the projected 2027 average. That marks a +20% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, REGN could reach as high as $1,103.10, with a base case around $821.90 and support toward $649.57 — roughly +31% from $627.74. Momentum favours further upside here.
Expect REGN to range from $715.12 to $1,252.38 through 2030. The $916.90 average target implies a +46% move from current prices. That is up +12% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The REGN price prediction for 2031 points to an average of $1,060.36 (low $817.13, high $1,470.90) — a potential gain of +69% on today's $627.74. Momentum favours further upside here.
In 2032, REGN is projected to trade between $832.41 and $1,536.47, averaging $1,092.28 — a potential gain of +74% from today's $627.74. That is up +3% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Regeneron Pharmaceuticals, Inc.'s 2033 outlook centres on $1,114.42, within a $840.50 to $1,587.71 range. That is up +2% on the projected 2032 average. That marks a +78% change versus current levels. Momentum favours further upside here.
By 2034, REGN could reach as high as $1,707.70, with a base case around $1,184.62 and support toward $884.69 — roughly +89% from $627.74. Buyers look set to stay in control over this stretch.
Expect REGN to range from $923.57 to $1,819.39 through 2035. The $1,248.31 average target implies a +99% move from current prices. That is up +5% on the projected 2034 average. Momentum favours further upside here.
The REGN price prediction for 2040 points to an average of $1,763.71 (low $1,251.31, high $2,693.03) — a potential gain of +181% on today's $627.74. Buyers look set to stay in control over this stretch.
In 2050, REGN is projected to trade between $2,309.98 and $5,712.78, averaging $3,491.34 — a potential gain of +456% from today's $627.74. That is up +98% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in REGN today (≈ 1.593016 REGN) could be worth
$5,561.76
+$4,561.76 (+456%) by 2050 · US Dollar
Based on the average projected REGN price of $3,491.34 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in REGNwould be worth at today's price.
$1,000 invested in REGN on May 27, 2025 (≈ 1.65766 REGN) would be worth
$1,040.58
+$40.58 (+4.1%) today · 1.04× · US Dollar
Based on a REGN entry price of $603.26 vs. today's $627.74.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $649.76 | $966.11 | -3.4% |
| 1 month ago | $744.44 | $843.24 | -15.7% |
| 3 months ago | $770.79 | $814.41 | -18.6% |
| 6 months ago | $780.19 | $804.6 | -19.5% |
| 1 year ago | $603.26 | $1,040.58 | +4.1% |
| All time (5.0y) ago | $503.23 | $1,247.42 | +24.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our REGN forecast.
Our base-case forecast reaches $1,300.00 around 2040.
Implied market cap at $1,300.00: $133.93B
In the multi-year forecast, 2026 lists an avg price of $638.88 with a 0% ROI and NEUTRAL sentiment. The path strengthens into 2027–2035, with the avg price rising to $1,268.13 by 2035 and ROI of 98.5%, supported by bullish sentiment in the later years. By 2030 the avg is $933.97 with a 46.2% ROI, and by 2040 the avg reaches $1,800.91 with an ROI of 181.9%; by 2050 the avg is $3,534.40 with an ROI of 453.2% and bullish sentiment across these long horizons.
These values are estimates, not guarantees, and actual results may vary.
Tap a question to reveal the answer.
Avg price: $933.97; min $727.55; max $1,277.69; ROI: 46.2%; sentiment: BULLISH.
Forecasts show NEUTRAL near term with 0% ROI in 2026 followed by bullish growth, with avg prices rising to $933.97 by 2030 and $3,534.40 by 2050; ROI reaches up to 453.2% by 2050.
Yes. The forecast max exceeds $1,000 in 2028 ($1,010.39) and continues higher to $1,277.69 by 2030 and up to $1,851.91 by 2035.
Current price: $638.88; Market cap: $66.98B.
Avg price: $1,800.91; min $1,274.98; max $2,756.05; ROI: 181.9%; sentiment: BULLISH.
Regeneron Pharmaceuticals, Inc. Community Discussion
0Share your Regeneron Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.